New hope for tough colorectal cancer: Triple-Drug attack
NCT ID NCT06369259
First seen Feb 14, 2026 · Last updated May 16, 2026 · Updated 14 times
Summary
This study tests whether a combination of three drugs—avutometinib, defactinib, and cetuximab—can help control advanced colorectal cancer that has stopped responding to standard treatments. About 33 adults with unresectable, anti-EGFR-refractory cancer will receive the drugs and be monitored for safety and side effects. The goal is to find a new way to manage the disease when other options have failed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77807, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.